Screener / SEC EDGAR /CIK 0001585364 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

PERRIGO Co plc PRGO

Compare with peers Embed
The 10-K against last year's

185 changes: 64 added, 36 removed, 83 reworded, 2 quiet changes

10-K Feb 26, 2026 vs Feb 28, 2025

10-K 0001585364-26-000009 (Feb 26, 2026) vs 10-K 0001585364-25-000014 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

207 paragraphs · 26 new · 56 reworded · 18 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 92 · 50% changed Every version of it
A Our exposure to cybersecurity breach, disruption or misuse of our threats and third‑party information systems, or our external business partners’ information systems system vulnerabilities could have result in a material adverse effect on our business.
Paragraph 130 · 49% changed Every version of it
We manufacture, source raw materials, and sell our products in a number of countries. The percentage of our business outside the U.S. has been increasing. We are subject to risks associated with international manufacturing and sales, including changes in regulatory requirements. Refer to Item 1. Business - Government Regulations Regulation and Pricing, for changes to tax and import/export laws and trade and customs policies (including the enactment of tariffs on goods imported into the U.S., including but not limited to, goods imported from China), problems related to markets with different cultural norms or political systems, possible difficulties in enforcing agreements, longer payment cycles and shipping lead-times, difficulties obtaining export or import licenses, and imposition of withholding or other taxes. Moreover, the trade policies of the new U.S. presidential administration could result in substantial changes to tax or fiscal policies that could impact our business. For example, the administration has imposed, or indicated a willingness to impose, significant tariffs on products imported from a number of countries, which could impact our API procurement, products and manufacturing, or give rise to retaliatory tariffs on U.S. goods by those countries. Pricing.
Paragraph 12 · 49% changed Every version of it
•Our ability to achieve operating results in line with published guidance is inherently subject to numerous risks significant uncertainties, and other factors beyond related stock-price volatility may heighten our control. Publishing earnings guidance subjects us susceptibility to risks, including increased stock volatility, that could lead to potential investor lawsuits by investors. and activist shareholder activity.
Paragraph 117 · 49% changed Every version of it
We perform an impairment analysis on intangible assets subject to amortization when there is an indication that the carrying amount of any individual asset may not be recoverable. Any significant change in market conditions, estimates or judgments used to determine expected future cash flows that indicates a reduction in carrying value may give rise to impairment in the period that the change becomes known. Goodwill, indefinite-lived intangible asset, and definite-lived intangible asset impairments are recorded in Impairment charges on the Consolidated Statements of Operations. As of December 31, 2024, the net book value of our goodwill and intangible assets were $3.3 billion and $2.4 billion, respectively. In the past three years, we have recognized a total of $178.9 million in asset impairments, across all segments and asset categories. Refer to Item 8. Note 9 for additional information related to our goodwill and intangible assets.
Paragraph 15 · 49% changed Every version of it
•We operate are subject to data privacy laws and regulations and our failure in jurisdictions that compliance could be affected by economic and geopolitical instability, which could have result in a material adverse effect on our business.
Paragraph 103 · 49% changed Every version of it
We operate are subject to data privacy laws and regulations and our failure in jurisdictions that compliance could be affected by economic and geopolitical instability, which could have result in a material adverse effect on our business.
Paragraph 16 · 49% changed Every version of it
•Management transition creates and our ability to attract and retain key personnel create uncertainties, and any difficulties we experience in managing such transitions which may negatively impact our business.
Paragraph 50 · 47% changed Every version of it
•Regulatory agencies globally, including the FDA and the European Medicines Agency, have issued guidance on assessing and controlling nitrosamine impurities in medicine products. Global regulators have stated that the nitrosamine impurity topic is evolving. We are continuing to undertake a review of our product portfolio in accordance be actively engaged with regulatory guidance the regulatory-based forums and associations to assess the risk of the presence of partner with, proactively contribute to, and respond accordingly to scientific advancements around nitrosamine impurities. Any As such, we continue to perform thorough risk assessments as outlined by guidance and initiating mitigation and control measures for any finding of nitrosamine impurities exceeding levels set by regulatory authorities authorities. These control measures may require us to adopt modified include modifying the product sourcing formulation and/or manufacturing processes or to initiate conducting additional product withdrawal. testing. If such measures are not successful, product withdrawal may be required.

MD&A

155 paragraphs · 38 new · 74 reworded · 18 gone · 10-K Feb 26, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 40 · 50% changed
Project Energize was initiated in the first quarter delivered approximately $167 million of 2024, subject to local law and consultation requirements, and is expected to deliver annualized pre-tax savings in as of the end of fiscal year 2025, within the estimated range of $140 million to $170 million expected by the end of 2026. The Company expects an annual reinvestment Reinvestment savings of $35 million over the same period are within the estimated range of approximately $40 million to $60 million of these savings to drive its business model. million. Restructuring and related charges associated with these actions were approximately $138 million over the same period are within the estimated to be in the range of $140 million to $160 million, including $20 million. For the remaining project wind-down activities, we anticipate less than $10 million to $40 million in investments to enhance capabilities, and are expected of additional costs to be substantially incurred by the end of through fiscal year 2026. Restructuring activities as part of Project Energize are expected to result in the net reduction of approximately 6% of total Perrigo roles. Refer to Item 8. Note 17 for further details on restructuring charges.
Paragraph 100 · 49% changed
The $423.8 $390.5 million decrease increase in financing cash flow was due primarily to larger one-time payments in the prior year period on the Senior Secured Credit Facilities compared to the pay down current year, partially offset by the prior year period issuance of the 2024 Notes utilizing cash on hand and proceeds from the sale of the Rare Diseases Business. Additionally, we redeemed in full $700 million in aggregate principal amount of the 4.375% senior notes due 2026 and made a principal prepayment of $391.0 million on the Term Loan B facility during the current year utilizing proceeds from debt issuances of approximately $1.1 billion from the 2032 Notes, as defined in Item 8. Note 12. Notes. Additionally, we increased our dividend payment by $2.8 $6.8 million compared to the prior year.
Paragraph 39 · 49% changed
As part of the Company's sustainable, value accretive growth strategy, the Company launched Project Energize - a global investment and efficiency program to drive the next evolution of capabilities and organizational agility. This three-year program is expected to produce significant benefits in the Company’s long-term business performance by enabling our One Perrigo growth strategy, increasing organizational agility and mitigating impacts from stabilizing and strengthening the infant formula business. As of December 31, 2025, Project Energize had achieved these objectives and has substantively completed.
Paragraph 85 · 48% changed
The $9.5 $14.1 million decrease in income during the year ended December 31, 2024 2025 compared to the prior year was due primarily to higher unfavorable changes in revaluation of foreign currency contracts associated with the planned divestiture of the Dermacosmetics Business, the absence of prior year milestone income related to legacy royalty rights. gain recognized on the sale of the Rare Diseases Business, and the loss recognized on the sale of the Richard Bittner Business.
Paragraph 90 · 47% changed
We finance our operations with internally generated funds, supplemented by credit arrangements with third parties and capital market financing. We routinely monitor current and expected operational requirements and financial market conditions to evaluate other available financing sources including term and revolving bank credit and securities offerings. In determining our future capital requirements, we regularly consider, among other factors, known trends and uncertainties, such as the war in Ukraine and conflicts in the Middle East, inflation and interest rates, the status of material contingent liabilities, recent financial market volatility and other uncertainties. Additionally, we have considered investments in capital expenditures related to the progression of infant formula plant investments, our Supply Chain Reinvention Program, and Project Energize. Subject to relevant restrictions under our debt agreements, our cash requirements for other purposes and other factors management deems relevant, we may from time to time use available funds to redeem, repurchase or refinance our debt in privately negotiated or open market transactions, by tender offer or otherwise, in compliance with applicable laws, rules and regulations, at prices and on terms we deem appropriate (which may be below par).
Paragraph 54 · 46% changed
•$50.6 •$66.5 million decrease from due to the prior year divestitures of the HRA Pharma Rare Diseases Business, Business (the "Rare Diseases Business") and the Orion Laboratories Hospital and & Specialty Business (the "Hospital & Specialty Business") and the sale of branded products; and products within our CSCI segment; partially offset by
Paragraph 147 · 46% changed
During the three months ending June 29, 2024, we recorded goodwill Our CSCA and CSCI reporting units had indications of potential impairment charge of $22.1 million related to our now divested Rare Disease reporting unit. During during the three months ended September 28, 2024, we recorded December 31, 2025, primarily driven by a sustained decrease in share price, lower expected cash flows principally related to infant formula market dynamics and a change in expectations of the broader self-care market for both the Americas and International business. We prepared quantitative analyses as of December 31, 2025 and determined the carrying value of the CSCA and CSCI reporting units exceeded their estimated fair value. We recognized a goodwill impairment charge of $5.4 $917.1 million for our CSCI CSCA, resulting in $1,168.8 million of goodwill in this reporting unit related to after the now divested Hospital & Specialty disposal group. During 2023, we recorded impairment and recognized a goodwill impairment charges of $90.0 million. $407.1 million for CSCI, resulting in $881.3 million of goodwill in this reporting unit after the impairment. We continue to monitor the progress of our reporting units and assess them for potential impairment should impairment indicators arise, as applicable, and at least annually during our fourth quarter impairment testing.
Paragraph 84 · 46% changed
The $9.5 $25.3 million decrease in income during the year ended December 31, 2024 2025 compared to the prior year was due primarily to higher the absence of interest expense associated with the de-designation of interest rate swap agreements in the prior year milestone income related to legacy royalty rights. and a decrease in interest expense associated with a decrease in outstanding borrowings under our Senior Secured Credit Facilities.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Accounting Policies240 words changed in this paragraph; it is 45% similar to last year's version.
Standard Description Effective Date Effect on the Financial Statements or Other Significant Matters ASU 2023-07: Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures This guidance improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. January 1, 2024 for annual periods, January 1, 2025 for interim periods As of January 1, 2024 we have adopted ASU 2023-07. This standard is adopted on a retrospective basis. Refer to Footnote 20-Segments for disclosure impact. ASU 2024-03: Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses This guidance aims to provide more detailed information about expenses to help investors better understand an entity's performance, assess future cash flows, and compare performance over time and with other entities. Entities must disclose specific quantitative and qualitative information about certain costs in the notes to financial statements. January 1, 2027 for annual periods, January 1, 2028 for interim periods As of December 31, 2024 2025, we are currently evaluating the potential disclosures impact of adopting the standard and whether to adopt retrospectively. ASU 2025-01: Reporting Comprehensive Income -Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date ASU 2023-09: Income Taxes Topic 740: Improvements to Income Tax Disclosures This guidance requires entities to annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). January 1, 2025 As of December 31, 2024 we are currently evaluating the potential disclosures impact of adopting the standard. We plan to adopt on a prospective basis and is not expected to have a material impact from additional disclosures.

Source: Item 8, Note 1 – NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001585364-26-000009 vs Item 8, Note 1 – NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001585364-25-000014

Legal Proceedings206 words changed in this paragraph; it is 34% similar to last year's version.
period from April 21, 2015 through November 13, 2015 and the allegedly inadequate disclosure throughout the entire class period related to the business developments during that longer period (April 2015 to May 2017) including purported integration problems related to the Omega acquisition, alleged incorrect reporting of organic growth at the Company and at Omega, alleged price fixing activities with respect to six generic prescription pharmaceuticals, and alleged improper accounting for the Tysabri® royalty stream. During 2017, the defendants filed motions to dismiss, which the plaintiffs opposed. On July 27, 2018, the court issued an opinion and order granting the defendants’ motions Following a motion to dismiss that was granted in part and denying denied in part in 2018, the motions to dismiss claims that remained in part. The court dismissed without prejudice defendants Laurie Brlas, Jacqualyn Fouse, Ellen Hoffing, Gary Cohen, Michael Jandernoa, Gerald Kunkle, Herman Morris, Donal O’Connor, and Marc Coucke. The court also dismissed without prejudice claims arising from the Tysabri® accounting issue described above and claims alleging incorrect disclosure of organic growth described above. The defendants who were not dismissed were the Company, Joe Papa, and Judy Brown. The claims (described above) that were not dismissed in 2018 case related to the integration issue regarding the Omega acquisition, the defense against the Mylan tender offer, and the alleged price fixing activities with respect to six generic prescription pharmaceuticals. The three defendants who remained in the case (us, Mr. (Perrigo and its former CEO, Joseph Papa, and Ms. former CFO, Judy Brown) filed answers in 2018 denying liability.

Source: Item 3, via Note 20 – COMMITMENTS AND CONTINGENCIES, 10-K 0001585364-26-000009 vs Item 3, via Note 19 – COMMITMENTS AND CONTINGENCIES, 10-K 0001585364-25-000014

Risk Factors175 words changed in this paragraph; it is 66% similar to last year's version.
•Our infant formula products may be subject to barriers or sanctions imposed by countries or international organizations limiting that limit international trade and dictating the content of such products. If or dictate product composition. As governments enhance impose new or more stringent regulations on the infant formula industry through actions such as requiring additional testing testing, or compulsory batch-by-batch inspection, or impose additional requirements on revised manufacturing practices, practice standards, our sales and operating margins in this category have been and could in the future be adversely affected as it is costly to comply with such new regulations or requirements, and to develop compliant products and processes for our infant formula products. For example, in March 2023, the FDA released its "Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market" and issued a letter to the powdered infant formula industry to share information to assist the industry in improving the microbiologic safety of powdered infant formula and resiliency of the infant formula market. In response to the FDA's evolving regulatory expectations on infant formula and observations at our facilities, we shortened our production campaigns to perform more frequent major cleanings, implemented enhanced product testing and quality procedures, adopted new manufacturing protocols, and made additional infrastructure investments. As a result, we These measures have been experiencing increased costs and lower reduced production volumes volumes, and we expect higher compliance costs moving forward. to continue. In March 2025, the U.S. Department of Health and Human Services (HHS) launched Operation Stork Speed, a regulatory initiative aimed at strengthening the safety, quality, transparency, and resilience of the U.S. infant formula supply. This initiative intends to review the nutrients used in infant nutrition, expand testing for contaminants, enhance labelling expectations, and will evaluate potential future regulatory updates. In addition, Operation Stork Speed extends the FDA’s personal importation policy, which allows individuals to import certain infant formula products for personal use, thereby potentially increasing competitive pressures in the U.S. infant formula market. Together, these measures may introduce new compliance and regulatory obligations and may affect competitive dynamics in the U.S. market.

Source: Item 1A, 10-K 0001585364-26-000009 vs Item 1A, 10-K 0001585364-25-000014

MD&A158 words changed in this paragraph; it is 49% similar to last year's version.
In 2022, we initiated a Supply Chain Reinvention Program to reduce structural costs, improve profitability and our service levels to our retail partners, and strengthen our resiliency by streamlining and simplifying our global supply chain. Through this initiative, we are reducing have reduced portfolio complexity, investing invested in advanced planning capabilities, diversifying diversified sourcing, and optimizing optimized our manufacturing assets and distribution models. We estimate a total annual run-rate potential savings opportunity by the end The program objectives are now realized with approximately $157 million of fiscal year 2028 of between $200 million to $300 million annualized benefits (not including related depreciation expense on capital investments). To obtain these potential benefits, we anticipate incurring costs between $300 million to $350 million investments) achieved by the end of fiscal year 2028 to complete the program implementation, with the substantial portion of the 2025. Total costs incurred by over the end of 2025, same period including capital investments, restructuring expenses and implementation costs. A significant portion costs totaled approximately $286 million. For the remaining project wind-down activities, we anticipate less than $10 million of the annual run-rate potential savings of the Program, between $150 million additional costs to $200 million (not including related depreciation expense on capital investments), are anticipated by the end of be incurred through fiscal year 2025. Refer to Item 8. Note 17 for further details on restructuring charges. 2026.

Source: Item 7, 10-K 0001585364-26-000009 vs Item 7, 10-K 0001585364-25-000014

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PRGO's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•Our inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, could result in a material adverse effect on our business, and the use of emerging technologies generally could result in regulatory action, legal liability, operational challenges or reputational harm.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Failure to effectively monitor our strategies, initiatives and risks related to environmental, social, sustainability and governance matters, as well as any actual or perceived inability to satisfy the evolving and diverging requirements and expectations of our investors, customers, regulators, employees, suppliers and other stakeholders with respect to such matters may negatively affect our business and operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
enhancement actions, experienced increased production costs and reduced production volumes, and expect higher compliance costs to continue. Moreover, if we are unable to address the FDA's past or future observations to the FDA's satisfaction, we could incur additional compliance costs, and our reputation could be adversely affected if we are perceived by consumers to not be in compliance with such framework.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Changes in the retail landscape and consumer behavior may adversely affect our business, financial condition, and results of operations. The increasing prevalence of alternative sales channels, such as e‑commerce, direct‑to‑consumer online brands, subscription services, and buying clubs, together with evolving consumer preferences, demand patterns, shopping behaviors, and consumption levels, may result in pressure on pricing, and shift market share in ways that are difficult to predict. These dynamics could adversely affect our business, results of operations, and financial condition.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our performance is also dependent on discretionary consumer spending, which is influenced by factors beyond our control, including general economic and political conditions, consumer confidence, interest rates, inflation, tax rates, credit availability, employment levels, and housing and financial market conditions. Deterioration in any of these factors could reduce customer spending and adversely affect our net sales and profitability. Our performance is also influenced by consumer trends, habits, and preferences. A shift away from traditional medicine or changes in other preferences could diminish demand for our products and reduce sales. As a result of these and other risks and uncertainties, our future sales, earnings, and cash flows could be volatile and vary materially from our expectations, including our published guidance.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our ability to achieve operating results in line with published guidance is inherently subject to significant uncertainties, and related share-price volatility may heighten our susceptibility to investor lawsuits and activist shareholder activity.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
A decline in our share price may also increase our vulnerability to activist shareholder actions. Responding to activist campaigns or a potential proxy contest may require significant time, attention, and resources from management and our Board and may result in substantial legal, advisory, and administrative expenses. Investor perception of activist activity may also increase share price volatility, and the associated distraction and resource demands could impede our ability to execute our business strategy and related strategic initiatives, adversely affecting our business, financial condition, and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 66
AddedRisk Factors
industrial espionage, interruptions or other system issues, unauthorized access and computer viruses. Such events may be difficult to detect, and once detected, their impact may be difficult to assess and address.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, could result in a material adverse effect on our business, and the use of emerging technologies generally could result in regulatory action, legal liability, operational challenges or reputational harm.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our ability to identify, adopt, and effectively integrate emerging technologies, including generative artificial intelligence (“AI”), into our product development, services, and operations is an important factor in maintaining our competitiveness. If we are unable to timely and responsibly leverage such technologies, our operating results, and growth prospects could be adversely affected. Increased use of AI introduces certain risks, including heightened exposure to cybersecurity threats, data privacy and intellectual property concerns, algorithmic errors or bias leading to flawed outputs or poor decision-making, and increased third-party dependency risks. Additionally, the legal and regulatory landscape governing AI is rapidly evolving in the United States and globally. Changes in, or noncompliance with, applicable laws, regulations, standards, and industry guidance could result in increased compliance costs, operational constraints, liability, or reputational harm. While we have implemented, and expect to continue enhancing, governance, security, and quality control measures related to the use of AI and other emerging technologies, these measures may not be effective in all cases, and we may incur significant costs or face unanticipated consequences as these technologies and their regulatory frameworks continue to develop.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
•The effects of public health outbreaks, including pandemics and epidemics, and related public and governmental actions could have a material adverse impact on our operations and our business and financial condition in the future.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•The synergies and benefits expected from acquiring HRA Pharma and Gateway may not be realized in the amounts anticipated or at all and integrating HRA Pharma and Gateway's business may be more difficult, time consuming or costly than expected.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
•Failure to effectively monitor and respond to ESG matters, including our ability to set and meet reasonable goals related to climate change and sustainability efforts, may negatively affect our business and operations.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The effects of public health outbreaks, including pandemics and epidemics, and related public and governmental actions could have a material adverse impact on our operations and our business and financial condition in the future.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Going forward, variants of COVID-19 or other public health incidents, including the actions taken to slow their spread, could have an adverse impact on our financial condition, our supply chains and other operations, our results of operations, consumer demand for our products and our ability to access capital. The magnitude of any such adverse impacts are not determinable, but could be material, depending on: the duration, intensity, and continued spread of the disease; the imposition of business or movement restrictions in various jurisdictions; the ability to develop vaccines and their availability, acceptance and efficacy; the severity and duration of any economic downturn resulting from such pandemic or other public health incidents; the effect of global supply chain and shipping challenges on the Company; the effectiveness of the Company's efforts at mitigation; and other factors, both known and unknown, many of which are likely to be outside our control.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Our ability to manufacture, deliver and sell our products is critical to our success. Damage or disruption to our collective supply or distribution capabilities resulting from pandemics and other health crises, including government
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
We have experienced significant changes to our leadership team over the past several years. Patrick Lockwood-Taylor was appointed President, Chief Executive Officer and Board Member in 2023. In 2024, the Company appointed new leaders of its CSCA and CSCI segments with the appointments of Catherine "Triona" Schmelter as President Consumer Self-Care Americas and Roberto Khoury as President Consumer Self-Care International. We also appointed Charles Atkinson as our new General Counsel and Abbie Lennox as our Chief Science Officer and
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
expanded our Chief Scientific Office, with Allison Ives tasked to head our new Disruptive Growth Team. Additionally, David Ball was appointed as Chief Brand and Digital Officer. Although we believe these leadership transitions are in the best interest of our stakeholders, any change in executive management creates uncertainty. Moreover, changes in our Company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Various factors may impact our ability to implement our strategies and realize their anticipated benefits. These factors include circumstances outside of our control such as increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses and changes in industry trends or consumer preferences. In addition, implementing these changes will require a significant amount of management time and effort, which may disrupt our business or otherwise divert management’s attention from other aspects of our business, including our other strategic initiatives, possible organic or inorganic growth opportunities, and customer and vendor relationships. Any of the foregoing risks could materially adversely affect our business, results of operations, liquidity, and financial condition.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The synergies and benefits expected from acquiring HRA Pharma and Gateway may not be realized in the amounts anticipated or at all and integrating HRA Pharma and Gateway's business may be more difficult, time consuming or costly than expected.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
We may experience challenges integrating the Gateway business and managing our expanded operations, including the acquisition of HRA Pharma. Our ability to realize the benefits expected from the HRA Pharma and Gateway acquisitions will depend, in part, on our ability to successfully integrate the business, control costs and maintain growth. Integrations can be complex and time consuming, and the integration may result in temporarily depressed sales while integration of supply chain and distribution channels take place. Any delays, additional unexpected costs, or other difficulties encountered in the integration process could have a material adverse effect on the Company’s revenues, expenses, operating results and/or financial condition. While the integration of HRA Pharma was completed during 2023, activities related to the integration of Gateway continued into 2024.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
If we are unable to recognize and adequately respond to such developments, or if our including by adapting existing practices and procedures are not adequate to meet new and changing regulatory requirements, market standards or investor expectations, some of which may be conflicting, we may miss corporate opportunities, become subject to regulatory or market scrutiny, litigation or third-party claims, or incur costs and be exposed to revise operations to meet new or revised standards. legal reputational, operational and financial risks.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Navigating Moreover, stakeholder expectations are not uniform on these matters and continue to diverge across different jurisdictions, and we may be unable to satisfy the varying expectations of all relevant policymakers and other stakeholders has inherent costs, and any actual or perceived failure to successfully navigate such expectations may expose us to negative publicity, shareholder activism, and litigation of or other engagement from stakeholders with opposing views, stakeholders, as well as the potential for civil investigations and enforcement by federal governmental authorities.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
These We have been in the past, are currently, and may be in the future, named in these types of lawsuits lawsuits, which can be costly and divert management attention and other resources away from our business, regardless of their merits, and could result in adverse settlements or judgments. judgments, which could have a material impact on our reputation, business, and results of operation.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
For example, after our acquisition of Gateway, Nestlé’s Gateway infant formula plant along with the U.S. and Canadian rights to the GoodStart® infant formula brand and other related formula brands ("Gateway"), in response to the FDA's evolving regulatory expectations on infant formula and observations at our facilities, we have shortened our production campaigns to perform more frequent major cleanings and implemented enhanced product testing and quality procedures, resulting in additional increased production costs and lower reduced production volumes of infant formula than previously anticipated.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We believe these initiatives will reduce operating costs and/or enhance our net sales, operating margins, and earnings; however, certain of these initiatives require substantial costs during implementation, and there can be no assurance any of these initiatives will produce the anticipated benefits. earnings.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If As governments enhance impose new or more stringent regulations on the infant formula industry through actions such as requiring additional testing testing, or compulsory batch-by-batch inspection, or impose additional requirements on revised manufacturing practices, practice standards, our sales and operating margins in this category have been and could in the future be adversely affected as it is costly to comply with such new regulations or requirements, and to develop compliant products and processes for our infant formula products.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We believe these initiatives will reduce operating costs and/or enhance our net sales, operating margins, and earnings; however, certain Certain of these initiatives require substantial management time and effort and costs during implementation, and there can be no assurance any of these initiatives will produce the anticipated benefits.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Item 7, 7 Management's Discussion and Analysis of Financial Condition and Results of Operations, in response to the warning letter from the FDA in August 2023 and additional inspection observations at our Wisconsin infant formula facility, we have implemented new protocols and made additional infrastructure investments to address these observations. observations and expect to continue to make such changes.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any increase in such costs or delay or failure to achieve the anticipated benefits could have a material adverse effect on materially adversely affect our projected results. business, results of operations, liquidity, and financial condition.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
As a result, we These measures have been experiencing increased costs and lower reduced production volumes volumes, and we expect higher compliance costs moving forward. to continue.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
While all sites have returned to reliable, quality-assured production, we incurred certain extraordinary costs associated with the remediation and enhancement actions and expect higher ongoing operating costs at our infant formula manufacturing sites moving forward.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In addition, an event of default under the Credit Agreement may permit the lenders to refuse to permit additional borrowings under the Revolver (as defined below) or to terminate all commitments to extend further credit under the Revolver. in Item 8.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
During the first quarter of 2026, we have begun transitioning from a geographic segment reporting structure to a category-based segment view, enabling us to better align our financial disclosures and operational analysis with our product offerings and strategic priorities. The change is being made to stay in alignment with the way our chief operating decision maker intends to make future operating decisions, allocate resources and manage the growth and profitability of the Company. The anticipated change is not expected to have any impact on the Company's historical consolidated financial position, results of operations, or cash flows.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Continuing uncertainties arising from increased tariffs on imported products could have an adverse effect on our Company. In 2025, the U.S. government announced new or additional tariffs on products imported from many countries and individualized "reciprocal" tariffs on countries with which the U.S. has the largest trade deficits. While some tariffs have become effective, others have been temporarily suspended, increased then reduced or permanently repealed. The U.S. government has announced trade agreements with various governments as well as additional tariffs on countries due to geo-political issues. As a result, there continues to be significant volatility and uncertainty regarding the scope, timing, implementation and effective rates of tariffs.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Based on current assessments, and excluding any potential impact from future pharmaceutical tariffs that may cover ingredients used in the manufacturing of OTC products, we estimate a gross increase to global cost of goods sold of approximately $30 million to $40 million, on a full-year basis beginning in 2026, updated from the previously estimated range of $50 million to $60 million. We continue to mitigate these impacts through a combination of strategic pricing actions, insourcing to our U.S.-based manufacturing facilities and other supply chain actions.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
for contaminants, and enhance labelling expectations, and will evaluate potential future regulatory updates. In addition, Operation Stork Speed extends the FDA’s personal importation policy, which allows individuals to import certain infant formula products for personal use, thereby potentially increasing competitive pressures in the U.S. infant formula market. Together, these measures may introduce new compliance and regulatory obligations and may affect competitive dynamics in the U.S. market.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
We have been focusing on rebuilding market share, while managing the additional cost and production processes. Although we have gained market share in non-WIC infant formula powder, heightened competition from existing and new entrants, particularly as a result of continued regulatory forbearance allowing imported infant formulas has led to increased supply of infant formula in the United States, and the previously disclosed lost distribution of the Good Start® brand have hindered our efforts to recover our previous market share. On November 5, 2025, we announced a strategic review of our infant formula business focused on a combination of accelerating cash flows and reassessing the previously announced investment in this business, while optimizing portfolio impact and management focus. See Nutrition Network Optimization; Strategic Review below.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In 2025, Perrigo initiated the Nutrition Network Optimization project to optimize our infant formula manufacturing footprint, upgrade packaging capabilities, harmonize quality processes, and enhance our research and development capabilities. On November 5, 2025, we announced a strategic review of our infant formula business. The review will assess a full range of alternatives and is aligned with Perrigo’s ‘Three‑S’ (Stabilize, Streamline, Strengthen) plan and reflects our commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the previously announced investment in this business of $240 million, while optimizing portfolio impact and management focus.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
Currently, all our infant formula manufacturing sites are up and running and have returned to reliable, quality-assured production with recent output across our infant formula network near historical levels. Our focus now lies in continuing to rebuild customer service levels and getting these critical products back on the shelves for consumers who need high-quality, affordable infant formula. With production now stabilized, we're driving strategic investments to strengthen the infant formula operations network to ensure the long-term sustainability of a key component of our CSCA business.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
On July 29, 2024, the Antitrust Division of the U.S. Department of Justice advised us that it no longer considers Perrigo a subject or target of the division’s grand jury investigation of antitrust violations in the generic drug industry. That investigation had stemmed from the Company’s Rx Pharmaceuticals business, which was divested in 2021.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Perrigo has successfully transformed into a pure-play consumer self-care company and is now embarking on the next stage of its self-care journey - evolving to One Perrigo. This evolution will create sustainable, value accretive growth through a business model that better positions the Company to win in self-care.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•$206.1 million decrease, or 4.5%, due primarily to $179.2 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health and Skin Care; and
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•$253.0 million decrease, or 8.6%, due primarily to $178.3 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health category, primarily driven by new product sales of Opill®; and
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
(1) We updated our global reporting product categories as a result of legacy sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Upper Respiratory: Net sales of $500.3 million decreased 10.9% due primarily to 7.3 percentage points reduction from portfolio optimization actions and net lost distribution of lower margin products, in addition to lower consumer demand for cough cold and allergy products. These impacts more than offset strong growth of Nasonex® and Triamcinolone Acetonide in the category;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Digestive Health: Net sales of $497.4 million decreased 2.0% as higher volumes of antacid and laxative products, including Polyethylene Glycol, were more than offset by 3.4 percentage points reduction from exited product lines and portfolio optimization actions, lost distribution of lower margin products in U.S. Store Brand and lower volume of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share gains;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Nutrition: Net sales of $449.5 million decreased 20.2% as increases in net sales of infant formula products as the Company continues to refill store brand and contract customer inventories and regain market share was more than offset by lower shipments to customers in the first half of the year as the Company worked through its infant formula plant remediation plans and a 0.8 percentage points decline from exited product lines in the category;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Pain and Sleep-Aids: Net sales of $345.5 million decreased 13.0% due primarily to net lost distribution of lower margin products, purposeful SKU prioritization actions and exited product lines, which had an aggregate negative impact of 10.3 percentage points. In addition, inventory reductions by U.S. retail customers resulted in lower net sales of pain and sleep-aid products;
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
•Women's Health: Net sales of $81.1 million increased 67.0% due primarily to the new product launch of Opill® and higher net sales of feminine hygiene products, partially offset by 3.9 percentage point reduction from exited product lines;
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
Future interest Interest rate adjustments of for the 3.150% Senior Notes due 2030 are subject to a 2.0% total cap above the original 3.150% interest rate which would result in an rate, ensuring that the interest rate does not to exceed 5.150% based on certain rating events as specified in the Note’s Supplemental Indenture No. 3, dated as of June 19, 2020, among Perrigo Finance Unlimited Company, Perrigo Company plc and Wells Fargo Bank, National Association, as trustee. 5.150%.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
On November 1, 2024, we completed the The sale of Orion Laboratories Hospital & Specialty Business (the "Hospital & Specialty Business") to General Pharma BidCo Pty Ltd, being an Australian incorporated entity which is ultimately owned by funds managed by Genesis Capital ("Genesis Capital") for total consideration of $13.3 million, which resulted in a pre-tax gain loss of $0.6 $1.6 million, net of professional fees, recorded in Other (income) expense, net on the Consolidated Statements of Operations within our CSCI segment.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
In On December 15, 2024, we and the Borrower entered into Amendment No. 2, an Incremental Assumption Agreement 2 to our the Credit Agreement, which established a new tranche of loans under the Term Loan B Facility (the "Term B Loans") and Revolving Credit Agreement that provides for the refinancing which refinanced all of the 2023 Incremental Term B Loans and the 2022 Term B Loans outstanding under the Credit Agreement in the aggregate principal amount of $984.7 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Future interest rate adjustments of the 3.150% Senior Notes due 2030 are subject to a 2.0% total cap above the original 3.150% interest rate which would result in an interest rate not to exceed 5.150% based on This adjustment is contingent upon certain rating events events, as specified outlined in the Note’s Supplemental Indenture No. 3, dated as of June 19, 2020, among Perrigo Finance Unlimited Company, Perrigo Company plc and Wells Fargo Bank, National Association, serving as trustee.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The effective tax rate on the pre-tax loss for the year ended December 31, 2024, increased 2025 decreased when compared to the effective tax rate on the pre-tax loss for the year ended December 31, 2023, 2024, primarily due to the impact of the One Big Beautiful Bill Act ("OBBBA") in 2025 and the net impact of an intercompany intellectual property sale, and sale in 2024, offset by the establishment of a partial full valuation allowance in the United States, offset by States and the impact of audit settlements the goodwill impairment charges in the prior year. 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Perrigo’s unique complementary businesses enables enable each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company’s key higher margin, higher growth or ‘High-Grow’ brands, 2) branding and innovation capabilities that deliver both brand and store brand demand generation leading designed to lead to stronger customer partnerships, 3) consumer-led innovation that is scaled across brands, store brands and geographies, and 4) the Company’s leveraging global supply chain scale and reach with 100-plus molecules, of more molecules at 100% consumer more price point coverage, serves the most consumers. points to more consumers driving household penetration.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net sales of $282.1 $288.2 million decreased 5.7%, increased 2.1%, inclusive of a 1.1% 4.0% favorable effect of currency translation, due primarily to lower net sales of cough cold products stemming from lower incidence of cough cold throughout the E.U. compared to the prior year, partially offset by higher net sales as well as an unfavorable impact of Bronchenolo®, Bronchostop® 1.5% from divested businesses and Coldrex® which benefited from category growth and market share gains; exited product lines.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The $156.3 $154.2 million increase decrease in cash from investing cash flow was due primarily to the absence of the proceeds from the sale of the Rare Diseases and Hospital & Specialty Businesses, proceeds from Businesses and the sale of six branded products in the current year, partially offset by the settlement of foreign currency derivatives and purchase of an intangible asset in the current year. prior year period.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The $42.6 $124.4 million decrease in operating cash inflow was primarily driven by a decrease in cash flow from the change in net earnings after adjustments for items including deferred income taxes, restructuring charges, settlement of interest rate derivatives, the gain on sale of branded products in addition to higher working capital, primarily related to restructuring costs. impairment, depreciation and amortization, and restructuring.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
All planned large-scale manufacturing plant improvements were completed in 2024, but the Company continues to implement the next phase of our resets have been completed, we have implemented quality enhancements, including further protocol, process and procedural improvements at the site level, and make additional investments to upgrade infrastructure. all sites are producing reliable, quality-assured product.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Year Ended (in millions) December 31, 2024 2025 December 31, 2023 2024 $ Change Net cash from operating activities $ 238.5 $ 362.9 $ 405.5 $ (42.6) (124.4) Net cash (for) from (for) investing activities (75.4) 78.8 (77.5) 156.3 (154.2) Net cash from (for) for financing activities (220.5) (611.0) (187.2) (423.8) 390.5 Effect of exchange rate changes on cash and cash equivalents 32.5 (23.2) 9.8 (33.0) 55.7 Net increase (decrease) decrease in cash and cash equivalents $ (24.9) $ (192.5) $ 150.6 $ (343.1) 167.6
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Project Energize was initiated in the first quarter delivered approximately $167 million of 2024, subject to local law and consultation requirements, and is expected to deliver annualized pre-tax savings in as of the end of fiscal year 2025, within the estimated range of $140 million to $170 million expected by the end of 2026.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRGO/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.